Skip to main content

EU/US/CTAD Task Force: Lessons Learned from Recent and Current Alzheimer's Prevention Trials.

Publication ,  Conference
Aisen, P; Touchon, J; Amariglio, R; Andrieu, S; Bateman, R; Breitner, J; Donohue, M; Dunn, B; Doody, R; Fox, N; Gauthier, S; Grundman, M ...
Published in: J Prev Alzheimers Dis
2017

At a meeting of the EU/US/Clinical Trials in Alzheimer's Disease (CTAD) Task Force in December 2016, an international group of investigators from industry, academia, and regulatory agencies reviewed lessons learned from ongoing and planned prevention trials, which will help guide future clinical trials of AD treatments, particularly in the pre-clinical space. The Task Force discussed challenges that need to be addressed across all aspects of clinical trials, calling for innovation in recruitment and retention, infrastructure development, and the selection of outcome measures. While cognitive change provides a marker of disease progression across the disease continuum, there remains a need to identify the optimal assessment tools that provide clinically meaningful endpoints. Patient- and informant-reported assessments of cognition and function may be useful but present additional challenges. Imaging and other biomarkers are also essential to maximize the efficiency of and the information learned from clinical trials.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Prev Alzheimers Dis

DOI

EISSN

2426-0266

Publication Date

2017

Volume

4

Issue

2

Start / End Page

116 / 124

Location

Switzerland

Related Subject Headings

  • United States
  • Outcome Assessment, Health Care
  • Nootropic Agents
  • Humans
  • European Union
  • Clinical Trials as Topic
  • Alzheimer Disease
  • Advisory Committees
  • 5204 Cognitive and computational psychology
  • 5202 Biological psychology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Aisen, P., Touchon, J., Amariglio, R., Andrieu, S., Bateman, R., Breitner, J., … Vellas, B. (2017). EU/US/CTAD Task Force: Lessons Learned from Recent and Current Alzheimer's Prevention Trials. In J Prev Alzheimers Dis (Vol. 4, pp. 116–124). Switzerland. https://doi.org/10.14283/jpad.2017.13
Aisen, P., J. Touchon, R. Amariglio, S. Andrieu, R. Bateman, J. Breitner, M. Donohue, et al. “EU/US/CTAD Task Force: Lessons Learned from Recent and Current Alzheimer's Prevention Trials.” In J Prev Alzheimers Dis, 4:116–24, 2017. https://doi.org/10.14283/jpad.2017.13.
Aisen P, Touchon J, Amariglio R, Andrieu S, Bateman R, Breitner J, et al. EU/US/CTAD Task Force: Lessons Learned from Recent and Current Alzheimer's Prevention Trials. In: J Prev Alzheimers Dis. 2017. p. 116–24.
Aisen, P., et al. “EU/US/CTAD Task Force: Lessons Learned from Recent and Current Alzheimer's Prevention Trials.J Prev Alzheimers Dis, vol. 4, no. 2, 2017, pp. 116–24. Pubmed, doi:10.14283/jpad.2017.13.
Aisen P, Touchon J, Amariglio R, Andrieu S, Bateman R, Breitner J, Donohue M, Dunn B, Doody R, Fox N, Gauthier S, Grundman M, Hendrix S, Ho C, Isaac M, Raman R, Rosenberg P, Schindler R, Schneider L, Sperling R, Tariot P, Welsh-Bohmer K, Weiner M, Vellas B. EU/US/CTAD Task Force: Lessons Learned from Recent and Current Alzheimer's Prevention Trials. J Prev Alzheimers Dis. 2017. p. 116–124.

Published In

J Prev Alzheimers Dis

DOI

EISSN

2426-0266

Publication Date

2017

Volume

4

Issue

2

Start / End Page

116 / 124

Location

Switzerland

Related Subject Headings

  • United States
  • Outcome Assessment, Health Care
  • Nootropic Agents
  • Humans
  • European Union
  • Clinical Trials as Topic
  • Alzheimer Disease
  • Advisory Committees
  • 5204 Cognitive and computational psychology
  • 5202 Biological psychology